GeneDx Holdings (WGS) Operating Income (2020 - 2026)

GeneDx Holdings (WGS) has reported Operating Income for 7 consecutive years, with -$17.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Income fell 294.81% year-over-year to -$17.5 million in Q2 2026; TTM through Jun 2026 was -$92.4 million, a 1800.31% decrease from a year earlier, with the FY2025 full-year figure at -$13.1 million, up 43.67% from the prior year.
• Operating Income was -$17.5 million for Q2 2026 at GeneDx Holdings, up from -$57.5 million in the prior quarter.
• Over five years, Operating Income peaked at $9.0 million in Q2 2025 and troughed at -$324.9 million in Q4 2022.
• A 5-year average of -$53.3 million and a median of -$21.5 million in 2023 frame the typical range for Operating Income.
• Across the five-year window, Operating Income jumped 184.7% in 2025 and sank 1162.82% in 2026, its largest moves.
• Over 5 years, Operating Income stood at -$324.9 million in 2022, then surged by 92.11% to -$25.6 million in 2023, then soared by 134.34% to $8.8 million in 2024, then plunged by 261.65% to -$14.2 million in 2025, then declined by 22.62% to -$17.5 million in 2026.
• The last three Operating Income figures came in at -$17.5 million (Q2 2026), -$57.5 million (Q1 2026), and -$14.2 million (Q4 2025), per Business Quant data.